Purple Biotech Ltd.
PPBT · NASDAQ
9/30/2025 | 6/30/2025 | 3/31/2025 | 12/31/2024 | |
|---|---|---|---|---|
| Valuation | ||||
| PEG Ratio | 0.00 | -0.00 | -0.00 | 0.16 |
| FCF Yield | 0.00% | -4,808.62% | -5,650.10% | -16.61% |
| EV / EBITDA | 7.47 | 4.42 | 14.89 | -5.54 |
| Quality | ||||
| ROIC | -4.14% | -3.83% | -4.25% | -3.04% |
| Gross Margin | 0.00% | 0.00% | 0.00% | 0.00% |
| Cash Conversion Ratio | 0.77 | 1.42 | 4.34 | 4.85 |
| Growth | ||||
| Revenue 3-Year CAGR | -100.00% | -100.00% | -100.00% | -100.00% |
| Free Cash Flow Growth | 100.00% | 21.84% | 1.79% | 38.88% |
| Safety | ||||
| Net Debt / EBITDA | 7.48 | 4.45 | 14.99 | 8.15 |
| Interest Coverage | -273.42 | 0.00 | -40.17 | 0.00 |
| Efficiency | ||||
| Inventory Turnover | 0.00 | 0.00 | 0.00 | 0.00 |
| Cash Conversion Cycle | -934.43 | -1,254.92 | -1,736.00 | -3,273.75 |